Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib vs Sorafenib plus HAIC in Advanced HCC
NCT03775395Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 12 months. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03775395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03775395.